How have IMLFF shares performed in 2024?

InMed Pharmaceuticals' stock was trading at $0.4160 at the beginning of 2024. Since then, IMLFF stock has decreased by 30.3% and is now trading at $0.29. View the best growth stocks for 2024 here .

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IMLFF

InMed Pharmaceuticals (IMLFF) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free IMLFF Stock Alerts

$0.29

-0.01 (-3.33%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.27
▼
$0.30
50-Day Range: $0.30
▼
$0.44
52-Week Range: $3.04
▼
$10.63

Volume: 60,355 shs
Average Volume: 11,369 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart

Get InMed Pharmaceuticals alerts:

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About InMed Pharmaceuticals Stock (OTCMKTS:IMLFF)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

IMLFF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMLFF Stock News Headlines

December 11, 2023 | benzinga.com

InMed's (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer's With A Rare Cannabinoid Analog

October 18, 2023 | benzinga.com

InMed Pharmaceuticals, A Cannabinoid-Focused Company, Sponsored Benzinga's Cannabis Capital Conference

April 19, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

May 16, 2023 | marketwatch.com

CannabisNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update

May 16, 2023 | msn.com

InMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To Know

March 21, 2023 | benzinga.com

InMed Pharmaceuticals Stock (NASDAQ:INM), Short Interest Report

January 21, 2023 | seekingalpha.com

INM InMed Pharmaceuticals Inc.

January 10, 2023 | technews.tmcnet.com

InMed Provides Business Update and Milestones for 2023

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

November 22, 2022 | msn.com

InMed Pharmaceuticals Secures $6M Via Private Placement

September 23, 2022 | benzinga.com

InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

September 13, 2022 | yahoo.com

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

September 9, 2022 | finance.yahoo.com

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market

August 24, 2022 | finanznachrichten.de

InMed Pharmaceuticals Inc.: InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

August 23, 2022 | finance.yahoo.com

InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria

June 15, 2022 | apnews.com

InMed Pharmaceuticals Closes $5M Direct, Private Placement Offerings

June 6, 2022 | finance.yahoo.com

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

June 1, 2022 | apnews.com

InMed Pharmaceuticals (INM): Health and Wellness Product Launches

November 10, 2021 | nasdaq.com

InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue Estimates

October 27, 2021 | benzinga.com

DeFi Will End Poorly Without Investor Protections, Gary Gensler Says

September 13, 2021 | benzinga.com

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

September 13, 2021 | benzinga.com

InMed Pharmaceuticals Inc. Enters Agreement For 'Transformative' Acquisition Of Leading Manufacturer Of Rare Cannabinoids

September 7, 2021 | benzinga.com

Where Do Blunts Come From? Who Was The First To Smoke One? Snoop Dogg Weighs In

September 6, 2021 | benzinga.com

What You Need To Know About CBD Hash

September 4, 2021 | benzinga.com

LEGAL: New, Stunning Web Series Looks Into The First Country To Legalize Cannabis And The People Thriving Thanks To It

September 2, 2021 | benzinga.com

Terpene Producer Eybna Teams Up With Cannabis Brands Spherex And Orchid Essentials

August 26, 2021 | benzinga.com

Can Ketamine Be Used To Treat Gambling Addiction? Awakn Life Sciences Wants To Find Out

See More Headlines

Receive IMLFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTCMKTS:IMLFF
CUSIP: N/A
CIK: N/A
Web: www.inmedpharma.com
Phone: (604) 669-7207
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Eric A. Adams (Age 56)
Pres, CEO & Director
Mr. Bruce S. Colwill C.A. (Age 55)
CPA, CA, CFO & Corp. Sec.
Ms. Alexandra D. J. Mancini (Age 67)
Sr. VP of Clinical & Regulatory Affairs
Dr. Eric Chih-Hsien Hsu (Age 50)
Sr. VP of Preclinical R&D
Mr. Michael Woudenberg P.Eng. (Age 53)
VP of Chemistry, Manufacturing & Controls
Dr. Sazzad Hossain
Co-Founder
Mr. Brendan Payne
Director of Investor Relations
Mr. Richard Hoy
VP of Sales & Marketing
Dr. Ado Muhammad
Sr. Consultant of Medical Affairs

Key Competitors

View All Competitors

IMLFF Stock Analysis - Frequently Asked Questions

How have IMLFF shares performed in 2024?: InMed Pharmaceuticals' stock was trading at $0.4160 at the beginning of 2024. Since then, IMLFF stock has decreased by 30.3% and is now trading at $0.29.
View the best growth stocks for 2024 here.
How do I buy shares of InMed Pharmaceuticals?: Shares of IMLFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMLFF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial